Despite chemotherapy regimens for advanced gastric cancer keep emerging, the patients still have poor prognosis. Molecular targeted therapy is another important direction for the treatment of advanced gastric cancer. Various drugs for molecular targeted therapy have been developed targeting epidermal growth factor receptor (EGFR), human epidermal growth factor receptor-2 (HER-2), vascular endothelial growth factor (VEGF) and its receptor (VEGFR), and cyclooxygenase-2 (COX-2); a number of Ⅱ/Ⅲ clinical trial have been completed or being conducted. The aim of this review is to summarize the recent progress on molecular targeted therapy for gastric cancer.